Nama Insights

Jazz Pharmaceuticals (JAZZ)

Healthcare · Biotechnology · NASDAQ

Jazz Pharmaceuticals (JAZZ) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $15.18B, a trailing price-to-earnings ratio of 16.0 and a free-cash-flow yield of 8.0%. Over the most recent reported fiscal year, revenue grew 4.9% and free cash flow per share fell 8.0%. Nama's AI scorecard rates it Buy, 6.0 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Buy · 6.0/10
Positive, at the low end of Buy. As of Nov 20, 2026.
Momentum
Rising · +20.6% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-13.6%
How far the last close sits under the highest price of the past five years.
Market cap$15.18B
Trailing P/E16.0
Price / book3.6
Price / sales3.2
FCF yield8.0%
Dividend yield—
Gross margin89.1%
Operating margin24.0%
Net margin4.4%
Revenue growth (YoY)+4.9%
Revenue growth (3-yr annual)+5.3%
EPS growth (YoY)-61.3%
FCF/share growth (YoY)-8.0%
Beta0.4
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

JAZZ earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate $6.66). Beat the EPS estimate in 2 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 2, 2026 -$3.88 -$2.38 -63.0% $1.24B
Q2 2026 Aug 3, 2026 $5.71 $6.18 -7.6% $1.21B
Q1 2026 May 5, 2026 $6.34 $4.66 +36.0% $1.07B
Q4 2025 Feb 24, 2026 $6.64 $6.51 +2.0% $1.20B

JAZZ analyst price target

Median target $300.00 from 22 analysts, ranging $220.00 – $330.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live JAZZ data on Nama Insights →

Recent Congressional trades

Jazz Pharmaceuticals trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Daniel Goldman House Sell $15,001 - $50,000 Aug 13, 2023

JAZZ FAQ

Is JAZZ a buy?
Nama's AI scorecard currently rates Jazz Pharmaceuticals Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is JAZZ's P/E ratio?
Jazz Pharmaceuticals trades at a trailing price-to-earnings ratio of 16.0.
When does JAZZ report earnings?
Jazz Pharmaceuticals's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $6.66.
What is the JAZZ price target?
The median analyst price target from 22 analysts is $300.00, with a range of $220.00 – $330.00.
Is JAZZ Shariah compliant?
Nama's AAOIFI-style screen reads Jazz Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.